SCHEMBL2457162

SCHEMBL2457162

CC(C)(C)OC(=O)N1CCCN(c2ccc3nc(-c4cccc(Cl)c4)n(C(C(N)=O)C(C)(C)C)c(=O)c3c2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AVPR1A P37288 2/20 0.42
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41
MAPT P10636 3/20 0.40
MAPK1 P28482 1/20 0.39
AVPR1B P47901 2/20 0.38
SUV39H2 Q9H5I1 1/20 0.38
JAK2 O60674 1/20 0.38
JAK3 P52333 1/20 0.38
GPR119 Q8TDV5 1/20 0.38
TP53 P04637 1/20 0.38
ALOX5 P09917 1/20 0.37
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37
KIT P10721 1/20 0.37
ATR Q13535 1/20 0.37
POLB P06746 1/20 0.37
P2RX7 Q99572 1/20 0.37
EGFR P00533 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2458954 0.90 P2RX7 (0.42) AVPR1ACKS1BSKP1SKP2SUV39H2
SCHEMBL2487317 0.86 ALK (0.41) CKS1BSKP1SKP2MAPTAVPR1B
SCHEMBL2458842 0.83 AVPR1B (0.41) AVPR1ACKS1BSKP1SKP2MAPT
SCHEMBL2457140 0.82 AVPR1B (0.60) AVPR1AAVPR1B
SCHEMBL2457166 0.81 AVPR1B (0.52) AVPR1AAVPR1B
SCHEMBL2461882 0.79 AVPR1B (0.60) AVPR1AAVPR1B
SCHEMBL5233509 0.74 MAPT (0.59) MAPTGPR119
SCHEMBL3452596 0.73 AVPR1B (0.51) AVPR1AAVPR1B
SCHEMBL2458754 0.73 AVPR1B (0.51) AVPR1AAVPR1B
SCHEMBL2458844 0.73 AVPR1B (0.61) AVPR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069315-B1 QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES ORGANON NV (NL) 2011-09-07 EP disclosed
US-7820649-B2 Quinazolinone and isoquinolinone acetamide derivatives N.V. ORGANON (NL) 2010-10-26 US disclosed
EP-2069315-A2 QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES N.V. Organon (NL) 2009-06-17 EP disclosed
US-20080090802-A1 QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES N.V. ORGANON (NL) 2008-04-17 US disclosed
WO-2008033764-A2 QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES N.V. ORGANON (NL) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090802-A1 QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES NQO2, GATD3, SDHA AVPR1A 859/4885CKS1B 1812/4885SKP1 1971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.